Esther H. Zhou

808 total citations
47 papers, 582 citations indexed

About

Esther H. Zhou is a scholar working on Toxicology, Pulmonary and Respiratory Medicine and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Esther H. Zhou has authored 47 papers receiving a total of 582 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Toxicology, 10 papers in Pulmonary and Respiratory Medicine and 9 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Esther H. Zhou's work include Pharmacovigilance and Adverse Drug Reactions (13 papers), Pharmaceutical Practices and Patient Outcomes (9 papers) and Health Systems, Economic Evaluations, Quality of Life (7 papers). Esther H. Zhou is often cited by papers focused on Pharmacovigilance and Adverse Drug Reactions (13 papers), Pharmaceutical Practices and Patient Outcomes (9 papers) and Health Systems, Economic Evaluations, Quality of Life (7 papers). Esther H. Zhou collaborates with scholars based in United States, Thailand and China. Esther H. Zhou's co-authors include Gerald J. Dal Pan, Mary E. Willy, Tarek A. Hammad, Aaron S. Kesselheim, Daniel S. Budnitz, Maribeth C. Lovegrove, Angelika D. Manthripragada, Jerry Avorn, Solomon Iyasu and Elizabeth M. Kang and has published in prestigious journals such as American Journal of Epidemiology, Journal of Allergy and Clinical Immunology and The Journal of Urology.

In The Last Decade

Esther H. Zhou

42 papers receiving 571 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Esther H. Zhou United States	16	110	98	82	81	78	47	582
Ruth Savage New Zealand	15	141 1.3×	83 0.8×	109 1.3×	69 0.9×	50 0.6×	33	1.2k
Liberata Sportiello Italy	24	90 0.8×	241 2.5×	126 1.5×	75 0.9×	78 1.0×	76	1.6k
Michele M. Spence United States	13	149 1.4×	47 0.5×	52 0.6×	104 1.3×	181 2.3×	24	1.2k
Laura Governale United States	13	49 0.4×	56 0.6×	66 0.8×	90 1.1×	54 0.7×	13	800
Mai Duong France	10	57 0.5×	42 0.4×	50 0.6×	82 1.0×	44 0.6×	13	710
Allen Brinker United States	16	121 1.1×	91 0.9×	43 0.5×	78 1.0×	51 0.7×	41	1.2k
Mio Sakuma Japan	16	52 0.5×	102 1.0×	77 0.9×	66 0.8×	42 0.5×	60	889
Murray Lumpkin United States	12	105 1.0×	65 0.7×	55 0.7×	133 1.6×	240 3.1×	27	782
Masayuki Hashiguchi Japan	16	100 0.9×	58 0.6×	55 0.7×	115 1.4×	40 0.5×	64	936
Roberto Da Italy	18	66 0.6×	36 0.4×	51 0.6×	52 0.6×	84 1.1×	65	747

Countries citing papers authored by Esther H. Zhou

Since Specialization

Citations

This map shows the geographic impact of Esther H. Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Esther H. Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Esther H. Zhou more than expected).

Fields of papers citing papers by Esther H. Zhou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Esther H. Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Esther H. Zhou. The network helps show where Esther H. Zhou may publish in the future.

Co-authorship network of co-authors of Esther H. Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Esther H. Zhou. A scholar is included among the top collaborators of Esther H. Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Esther H. Zhou. Esther H. Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sarpatwari, Ameet, Zhigang Lu, Massimiliano Russo, et al.. (2025). Physician Experiences With and Perspectives on Clozapine Prescribing. JAMA Network Open. 8(2). e2459311–e2459311.

Bui, Elise T., et al.. (2024). Prescriber perceptions of boxed warnings: A qualitative study. Pharmacoepidemiology and Drug Safety. 33(3). e5766–e5766. 1 indexed citations

Winterstein, Almut G., Yanning Wang, Leila G. Lackey, et al.. (2024). Teratogenic Risk Impact and Mitigation (TRIM): Study Protocol for the Development of a Decision Support Tool to Prioritize Medications for Risk Mitigation. Drug Safety. 48(2). 107–117.

Wu, Leihong, et al.. (2024). Description and Validation of a Novel AI Tool, LabelComp, for the Identification of Adverse Event Changes in FDA Labeling. Drug Safety. 47(12). 1265–1274. 1 indexed citations

Feldman, William B., Mufaddal Mahesri, Ameet Sarpatwari, et al.. (2024). Removing the FDA’s Boxed Hepatotoxicity Warning and Liver Function Testing Requirement for Ambrisentan. JAMA Network Open. 7(7). e2419873–e2419873.

Zhou, Esther H., et al.. (2023). The Risk Evaluation and Mitigation Strategy (REMS) Public Dashboard: Improving Transparency of Regulatory Activities. Pharmaceutical Medicine. 37(5). 349–353. 1 indexed citations

Re, Vincent Lo, Dena M. Carbonari, Jerry Jacob, et al.. (2021). Validity of ICD‐10‐CM diagnoses to identify hospitalizations for serious infections among patients treated with biologic therapies. Pharmacoepidemiology and Drug Safety. 30(7). 899–909. 18 indexed citations

Sarpatwari, Ameet, Katsiaryna Bykov, Jerry Avorn, et al.. (2021). A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) Programs. Drug Safety. 44(7). 743–751. 9 indexed citations

Kesselheim, Aaron S., Michael S. Sinha, Eric G. Campbell, et al.. (2019). Multimodal Analysis of FDA Drug Safety Communications: Lessons from Zolpidem. Drug Safety. 42(11). 1287–1295. 13 indexed citations

10.

Sinha, Michael S., Clark C. Freifeld, John S. Brownstein, et al.. (2018). Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging About Zolpidem: Mixed-Methods Analysis. JMIR Public Health and Surveillance. 4(1). e1–e1. 20 indexed citations

11.

Zhu, Yanmin, et al.. (2018). Concomitant use of buprenorphine for medication-assisted treatment of opioid use disorder and benzodiazepines: Using the prescription behavior surveillance system. Drug and Alcohol Dependence. 187. 221–226. 17 indexed citations

12.

Kesselheim, Aaron S., Macarius Donneyong, Gerald J. Dal Pan, et al.. (2017). Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications. Pharmacoepidemiology and Drug Safety. 26(6). 712–721. 25 indexed citations

13.

Schwartz, Lisa M., et al.. (2017). Media Coverage of FDA Drug Safety Communications about Zolpidem: A Quantitative and Qualitative Analysis. Journal of Health Communication. 22(5). 365–372. 16 indexed citations

14.

Butler, Melissa G., Esther H. Zhou, Ann Chen Wu, et al.. (2015). Changing patterns of asthma medication use related to US Food and Drug Administration long-acting β2-agonist regulation from 2005-2011. Journal of Allergy and Clinical Immunology. 137(3). 710–717. 15 indexed citations

15.

Zhou, Esther H., Elizabeth M. Kang, Samantha Seymour, & Solomon Iyasu. (2014). Long-acting beta₂-adrenergic agonist in pediatric and adolescent asthma patients, 2003–2011. Journal of Asthma. 51(10). 1061–1067. 3 indexed citations

16.

Zhou, Esther H., Sigal Kaplan, Andrew D. Mosholder, et al.. (2013). Antidepressant medication dispensing among montelukast initiators. Journal of Asthma. 50(9). 990–995. 9 indexed citations

17.

Pinheiro, Simone, et al.. (2013). Concomitant use of isotretinoin and contraceptives before and after iPledge in the United States. Pharmacoepidemiology and Drug Safety. 22(12). 1251–1257. 33 indexed citations

18.

Du, Dongyi, et al.. (2012). Atomoxetine Use During a Period of FDA Actions. Medical Care. 50(11). 987–992. 16 indexed citations

19.

Ellis, Rodney J., et al.. (2009). Long-term Outcomes Following IGRT for Localized Prostate Cancer: Dose Escalation to SPECT/CT Determined Biologic Target Volumes and the bDFS Predictive Value of Capromab Pendetide. International Journal of Radiation Oncology*Biology*Physics. 75(3). S45–S45. 1 indexed citations

20.

Ellis, Rodney J., Esther H. Zhou, Ping Fu, et al.. (2008). Single Photon Emission Computerized Tomography With Capromab Pendetide Plus Computerized Tomography Image Set Co-Registration Independently Predicts Biochemical Failure. The Journal of Urology. 179(5). 1768–1774. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact